Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3751-3760 Newer>

The Motley Fool May 30, 2007 Brian Lawler	Genzyme Gobbles Up a Partner Another day, another biotech acquisition for drugmaker Genzyme. Investors, with more than $500 million in free cash flow last year alone, Genzyme has money to spare.
The Motley Fool May 29, 2007 Brian Lawler	One Final Look at the Old Mylan With the Merck acquisition not expected to be accretive to earnings for at least two years, the question is if Mylan leveraged its financial health too far in its quest to get bigger and keep up in this buyout race.
The Motley Fool May 29, 2007 Brian Lawler	Nektar Squeezes Itself Nektar Therapeutics cuts costs after a slower rollout of its lead compound. Investors, take note.
The Motley Fool May 29, 2007 Brian Lawler	The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids.
The Motley Fool May 29, 2007 Brian Lawler	Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note.
The Motley Fool May 25, 2007 Brian Orelli	Amylin Sifts for Gold The biotech mines extra value from its compound library. Investors, take note.
The Motley Fool May 25, 2007 Brian Lawler	Bristol-Myers Tries to Boost Abilify Bristol-Myers announces new data for one of its top compounds. Investors, take note.
The Motley Fool May 25, 2007 Brian Lawler	BioMarin Waits for Another Drug BioMarin files a marketing application for its lead compound in development. Investors, take note.
The Motley Fool May 24, 2007 Mike Havrilla	A New Era at AEterna A strong balance sheet and a pair of promising products underlie optimism for the biopharmaceutical's future prospects.
The Motley Fool May 24, 2007 Ryan Fuhrmann	Chronic Healthiness at Medtronic The med-tech firm isn't growing as fast as it once was, but its fourth-quarter earnings report still managed to beat Wall Street's expectations.
<Older 3751-3760 Newer> Return to current articles.